Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. 1992

R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
Department of Pharmacokinetics, Miles Inc., West Haven, Connecticut 06516.

This study was designed to determine the effects of an aluminum hydroxide antacid and a calcium carbonate antacid on the bioavailability of ciprofloxacin (Cipro). Cipro (750 mg) was administered orally to 12 healthy volunteers in a three-way randomized crossover design. The three treatments included Cipro alone, four 850-mg calcium carbonate tablets taken 5 min before Cipro, and three 600-mg aluminum hydroxide tablets taken 5 min before Cipro. The relative bioavailability of Cipro when given with calcium carbonate was approximately 60% of the control value. When Cipro was given with aluminum hydroxide, the relative bioavailability was approximately 15%. Urinary recovery of Cipro in the aluminum hydroxide treatment group was approximately one-fourth of that in the calcium carbonate group. Although calcium carbonate decreased absorption to a lesser extent than aluminum hydroxide, these data suggest that antacids containing either aluminum or calcium should not be given concomitantly with Cipro.

UI MeSH Term Description Entries
D008297 Male Males
D002119 Calcium Carbonate Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement. Aragonite,Calcite,Chalk,Limestone,Marble,Milk of Calcium,Vaterite,Calcium Milk,Carbonate, Calcium
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000536 Aluminum Hydroxide A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc. Hydrated Alumina,Aldrox,Algeldrate,Alhydrogel,Alugel,Amphojel,Basalgel,Brasivil,Dialume,Nephrox,Pepsamer,Rocgel,Alumina, Hydrated,Hydroxide, Aluminum
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
December 1990, Antimicrobial agents and chemotherapy,
R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
April 1988, Digestive diseases and sciences,
R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
January 1943, The Journal of clinical investigation,
R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
December 1989, Clinical pharmacology and therapeutics,
R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
April 1960, Journal of the American Pharmaceutical Association. American Pharmaceutical Association,
R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
January 1986, ASAIO transactions,
R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
February 1996, Clinical nephrology,
R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
December 1983, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
November 2007, Clinical journal of the American Society of Nephrology : CJASN,
R W Frost, and K C Lasseter, and A J Noe, and E C Shamblen, and J T Lettieri
January 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Copied contents to your clipboard!